GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (NAS:FOLD) » Definitions » Price-to-Tangible-Book

Amicus Therapeutics (Amicus Therapeutics) Price-to-Tangible-Book : (As of Apr. 27, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Price-to-Tangible-Book?

As of today (2024-04-27), Amicus Therapeutics's share price is $10.28. Amicus Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-0.20. Hence, Amicus Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for Amicus Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, Amicus Therapeutics's highest Price to Tangible Book Ratio was 92.36. The lowest was 9.08. And the median was 16.52.

FOLD's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.68
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Amicus Therapeutics's share price is $10.28. Amicus Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.55. Hence, Amicus Therapeutics's P/B Ratio of today is 18.83.


Amicus Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Amicus Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Price-to-Tangible-Book Chart

Amicus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.73 92.36 37.26 - -

Amicus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Amicus Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Amicus Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amicus Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's Price-to-Tangible-Book falls into.



Amicus Therapeutics Price-to-Tangible-Book Calculation

Amicus Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=10.28/-0.198
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Amicus Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Amicus Therapeutics (Amicus Therapeutics) Business Description

Traded in Other Exchanges
Address
3675 Market Street, Philadelphia, PA, USA, 19104
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Executives
John F Crowley director, officer: Executive Chairman C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
David Michael Clark officer: Chief People Officer 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Samantha Prout officer: Principal Accounting Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradley L Campbell director, officer: President and CEO C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ellen Rosenberg officer: General Counsel & Corp. Secy C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560
Jeff Castelli officer: VP, Program Management 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Harford Simon N.r. officer: Chief Financial Officer AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Michael Raab director 1119 ST PAUL STREET, BALTIMORE MD 21202
Daphne Quimi officer: Chief Financial Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100
Burke W Whitman director 13455 NOEL ROAD # 2000, DALLAS TX 75240
Eiry Roberts director C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Hung Do officer: Sr Vice President Discovery C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Michael Aaron Kelly director C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Jay Barth officer: Chief Medical Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512